Document is current
Any future updates will be listed below
-
Authors
Zhou, Biao
Zhou, Runhong
Tang, Bingjie https://orcid.org/0000-0002-2900-0392
Chan, Jasper Fuk-Woo https://orcid.org/0000-0001-6336-6657
Luo, Mengxiao
Peng, Qiaoli
Yuan, Shuofeng
Liu, Hang https://orcid.org/0000-0002-6176-3963
Mok, Bobo Wing-Yee
Chen, Bohao
Wang, Pui
Poon, Vincent Kwok-Man https://orcid.org/0000-0002-7737-8912
Chu, Hin https://orcid.org/0000-0003-2855-9837
Chan, Chris Chung-Sing https://orcid.org/0000-0001-7089-4829
Tsang, Jessica Oi-Ling
Chan, Chris Chun-Yiu
Au, Ka-Kit
Man, Hiu-On
Lu, Lu
To, Kelvin Kai-Wang https://orcid.org/0000-0002-1921-5824
Chen, Honglin https://orcid.org/0000-0001-5108-8338
Yuen, Kwok-Yung https://orcid.org/0000-0002-2083-1552
Dang, Shangyu https://orcid.org/0000-0001-9141-1865
Chen, Zhiwei https://orcid.org/0000-0002-4511-2888
- License Information
-
More Information
Article History
Received: 19 January 2022
Accepted: 7 June 2022
First Online: 23 June 2022
Competing interests
: The authors declare no conflicts of interest except for a provisional patent application filed for human monoclonal antibodies generated in our laboratory with Z.C., B.Z., and R.Z. as the co-inventers. J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited. The funding sources had no role in study design, data collection, analysis or interpretation, or writing of the report.
